论文部分内容阅读
头孢洛林酯是新型注射给药的广谱头孢菌素类抗生素,对革兰阳性菌,包括耐甲氧西林金黄色葡萄球菌(MRSA)和多药耐药肺炎链球菌(MDRSP)以及常见革兰阴性菌具有杀菌活性。2010年10月29日,美国FDA批准其用于治疗成人社区获得性细菌肺炎(CABP)和急性细菌皮肤和皮肤结构感染(ABSSSI),包括MRSA的感染。文中对其抗菌活性、药动学/药效学、临床疗效、不良反应等做一综述。
Ceftaroline fosamil is a new broad-spectrum cephalosporin-based antibiotic for injection against Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and multidrug-resistant Streptococcus pneumoniae (MDRSP) Blue-negative bacteria have bactericidal activity. On October 29, 2010, the U.S. FDA approved its use for the treatment of adult community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI), including infections with MRSA. The article reviews its antibacterial activity, pharmacokinetics / pharmacodynamics, clinical efficacy, adverse reactions and so on.